A5069029347- Diabetes Treatment and Management
- Diabetes Management and Research
- Pancreatic function and diabetes
- Metabolism, Diabetes, and Cancer
- Amino Acid Enzymes and Metabolism
- Epigenetics and DNA Methylation
- Drug Transport and Resistance Mechanisms
Astellas Pharma (Japan)
2019-2020
Ibero American University
2020
Tokyo University of Pharmacy and Life Sciences
2008
Abstract Aim To assess the efficacy and safety of once‐daily ipragliflozin 50 mg versus placebo in Japanese people with type 1 diabetes mellitus (T1DM) inadequately controlled insulin. Materials methods We conducted a multicentre, double‐blind, parallel‐group, placebo‐controlled phase 3 study. Participants (N = 175) were randomized (2:1) to receive (n 115) or 60), combined insulin, for 24 weeks. The primary endpoint was change glycated haemoglobin (HbA1c); key secondary endpoints included...
To evaluate the pharmacodynamics, pharmacokinetics, and safety of novel oral sodium-glucose co-transporter-2 inhibitor, ipragliflozin, in Japanese patients with type 1 diabetes mellitus.We conducted a multicentre, double-blind, placebo-controlled, parallel-group study. Patients were randomized to receive 25, 50, or 100 mg/day ipragliflozin placebo for 2 weeks. Key pharmacokinetic endpoints included area under concentration-time curve 24 hours postdose (AUC24h ), maximum plasma concentration...
Abstract Organic solute carrier protein 1 (OSCP1) is a recently described human gene that facilitates the transport of various organic solutes into cell, when expressed in frog eggs. In this study, we cloned mouse ortholog OSCP1 encoding 379 amino acid protein, with 94% homology to counterpart. The mRNA was predominantly testis, which it attributed spermatogenic cells, except spermatogonia. Immunohistochemistry confirmed continuously during spermatogenesis stage‐ and cell type‐specific...
The aim of the present study was to assess long-term (52-week) efficacy and safety ipragliflozin in insulin-treated Japanese patients with type 1 diabetes mellitus inadequate glycemic control.